ART Likely Less Effective in Women With HIV Versus Other Chronic Viral Illnesses ART Likely Less Effective in Women With HIV Versus Other Chronic Viral Illnesses
HIV-infected women who underwent assisted reproductive technology (ART) had a lower live birth rate than those with chronic hepatitis B or hepatitis C virus in a cohort study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 1, 2021 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

How DaVita is working to directly administer Covid-19 vaccines to patients across the country
The Denver-based kidney care company is using the processes it developed for flu and Hepatitis B vaccines and applying them to Covid-19. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 30, 2021 Category: American Health Authors: Jensen Werley Source Type: news

How DaVita is working to directly administer Covid-19 vaccines to patients across the country
The Denver-based kidney care company is using the processes it developed for flu and Hepatitis B vaccines and applying them to Covid-19. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 30, 2021 Category: Biotechnology Authors: Jensen Werley Source Type: news

Hepatitis B: What people can learn from donkeys
(German Center for Infection Research) The discovery of a previously unknown hepatitis B virus in donkeys and zebras opens up new opportunities for understanding the course of the disease. A global research consortium was able to show that the course of the infection with this virus is similar to that of chronic hepatitis B in humans. The study was led by DZIF scientists at the Charit é - Universit ä tsmedizin Berlin and the Justus Liebig University Giessen. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2021 Category: International Medicine & Public Health Source Type: news

New study provides detailed view of how hepatitis B virus establishes chronic infection
(Princeton University) Researchers identified five proteins that are necessary for hepatitis B virus infection, which kills more than 850,000 people worldwide each year and has no cure. The research on the viral life cycle could eventually help identify drugs that block infection. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 11, 2021 Category: International Medicine & Public Health Source Type: news

Venatorx adds potential chronic hepatitis B treatment to its pipeline
A Chester County pharmaceutical company said Wednesday it has selected a clinical candidate it intends to develop as a treatment for chronic hepatitis B virus infections. Venatorx Pharmaceuticals, an antibiotic developer that was founded in 2010 and is based in Malvern, has long had hepatitis B on its list of targets. An estimated 200,000 new cases of hepatitis B, a serious liver infection, are diagnosed in the U.S each year. More than 250 million people worldwide have chronic hepatitis B. Venatorx's… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 10, 2021 Category: American Health Authors: John George Source Type: news

Ghana: Stakeholders Call for Hepatitis B, Malaria Testing Guidelines
[Ghanaian Times] Stakeholders at a Hepatitis B and Malaria (HEPMAL) workshop yesterday called for a National Testing Guidelines for the eradication of Hepatitis B and Malaria. (Source: AllAfrica News: Malaria)
Source: AllAfrica News: Malaria - March 8, 2021 Category: Infectious Diseases Source Type: news

Risk Factors for Development of HCC in Chronic HBV Infection Risk Factors for Development of HCC in Chronic HBV Infection
How do various metabolic factors and comorbidities influence hepatocellular carcinoma risk in patients with chronic hepatitis B infection?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 4, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New combination therapy offers chance of healing hepatitis B
(German Center for Infection Research) Around 260 million people, more than three percent of the global population, are chronically infected with the hepatitis B virus (HBV); in the long term, this often leads to complications such as liver cirrhosis and liver cancer. A cure is not yet possible with the available medication. Scientists at the German Center for Infection Research (DZIF) and the University Hospital Eppendorf (UKE) have now investigated a new combination therapy that has proven highly effective in their infection model. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 4, 2021 Category: Infectious Diseases Source Type: news

New biosensors quickly detect coronavirus proteins and antibodies
(University of Washington Health Sciences/UW Medicine) Researchers have designed protein-based biosensors that glow when mixed with targeted molecules, such as components of the pandemic coronavirus or specific COVID-19 antibodies. This development could allow for faster, more widespread testing in the near future. Similar biosensors could be designed to detect medically relevant human proteins such as Her2 (a biomarker for some breast cancers) and Bcl-2 (which has clinical significance in some other cancers), as well as a bacterial toxin and antibodies that target Hepatitis B virus. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 28, 2021 Category: Cancer & Oncology Source Type: news

Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holde...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Science - January 11, 2021 Category: Science Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

New viral detection technique uses smartphone camera to diagnose various infections
(American Association for the Advancement of Science) Scientists have developed a novel smartphone-based technique to diagnose viral infections that uses a deep learning algorithm to identify viruses in metal nanoparticle-labeled samples, enabling rapid virus detection without the need for skilled laboratory workers and expensive equipment. The system correctly identified clinically relevant concentrations of Zika, hepatitis B (HBV), or hepatitis C (HCV) in 134 patient samples with 98.97% sensitivity. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 16, 2020 Category: Infectious Diseases Source Type: news

USPSTF Recommends Hep B Screen for At-Risk Teens, Adults
TUESDAY, Dec. 15, 2020 -- The U.S. Preventive Services Task Force (USPSTF) concludes that screening adults and adolescents at increased risk for hepatitis B virus (HBV) infection has moderate net benefit. These findings form the basis of a final... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 15, 2020 Category: Pharmaceuticals Source Type: news

USPSTF statement on screening for hepatitis B virus infection in adolescents, adults
(JAMA Network) The   US Preventive Services Task Force (USPSTF) recommends screening for hepatitis B virus   infection in adolescents and adults at increased risk for infection.   (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 15, 2020 Category: Infectious Diseases Source Type: news

The Ambulance Science Podcast: Make Up Your Own Mind About the Vaccine
Get every episode of The Ambulance Science Podcast by subscribing to Apple Podcasts or Google Podcasts. Where I’m coming from (compared to most of my colleagues): Master’s in Public Health with a concentration in Health Policy from Yale Medical School.FT Faculty at GWU School of Medicine & Southern Connecticut State University MPH Program, and long-time adjunct faculty at NYMC MPH program in Health Policy.Assistant Commissioner of Health at the NYC Department of Health & Mental Hygiene during the first SARS outbreak.Served as State EMS Director, Consultant to Public Health ...
Source: JEMS Special Topics - December 14, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Podcasts Ambulance Science Source Type: news

Aspirin and Statins in Chronic Hepatitis B: It's Complicated Aspirin and Statins in Chronic Hepatitis B: It's Complicated
Statins play a bigger part than aspirin in reducing risk for hepatocellular carcinoma in patients with hepatitis B, new research shows, and cirrhosis seems to cancel any beneficial effect of aspirin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 19, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Mixed Outcomes in Tenofovir Trial for Chronic Hepatitis B Mixed Outcomes in Tenofovir Trial for Chronic Hepatitis B
Levels of surface antigen loss were low whether or not patients treated with tenofovir also received interferon, but some patients met criteria for inactive chronic disease after therapy withdrawal.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Researchers discover enzyme suppressing immune response to viral infections
(University of Missouri-Columbia) Viruses such as HIV, hepatitis B and hepatitis C evade or disrupt the immune system to create persistent infections. These viruses remain a serious health threat, but researchers from the University of Missouri School of Medicine have discovered how an enzyme that regulates several cellular processes might be a key target to preventing viruses from disarming the human immune response. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 10, 2020 Category: Cancer & Oncology Source Type: news

Sexually transmitted infections in women deprived of liberty in Roraima, Brazil - Benedetti MSG, Nogami ASA, Costa BB, Fons êca HIF, Costa IDS, Almeida IS, Miranda L, Conchy MMM, Bentes RS, Higa SN, Israel TS, Fonseca AJ.
OBJECTIVE: To evaluate the prevalence of HIV, syphilis and hepatitis B infection among women deprived of liberty in the state of Roraima, Brazil, and its correlation with perceptions, knowledge and behavioral factors. METHOD: This is a cross-sectional ... (Source: SafetyLit)
Source: SafetyLit - November 7, 2020 Category: International Medicine & Public Health Tags: Risk Factor Prevalence, Injury Occurrence Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news

Ontario should vaccinate newborns for hepatitis B, study suggests
(Canadian Medical Association Journal) Not all pregnant women are universally screened for hepatitis B virus (HBV) in Ontario, even though this screening is recommended, and the majority of those who test positive do not receive follow-up testing or interventions, leading to infections of newborns, found new research in CMAJ (Canadian Medical Association Journal). (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 26, 2020 Category: Infectious Diseases Source Type: news

Qui én realmente necesita la vacuna de hepatitis B
¿Quiénes realmente necesitan la vacuna de hepatitis B? ... Las personas con diabetes tienen el doble de probabilidad de infectarse con hepatitis B, una enfermedad grave y mortal que afecta el hígado. (Source: AARP.org News)
Source: AARP.org News - October 24, 2020 Category: American Health Source Type: news

HIV Drugs Prevent Type 2 Diabetes, May Be Path to New Therapy HIV Drugs Prevent Type 2 Diabetes, May Be Path to New Therapy
An analysis of five databases shows that the NRTIs used to treat HIV and hepatitis B infection are able to prevent diabetes by blocking inflammasone activation; discovery may pave way for new therapeutics.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 22, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

3 Win Nobel Medicine Prize for Discovering Hepatitis C Virus
(STOCKHOLM) — Americans Harvey J. Alter and Charles M. Rice and British-born scientist Michael Houghton won the Nobel Prize for medicine on Monday for their discovery of the hepatitis C virus, a major source of liver disease that affects millions worldwide. Announcing the prize in Stockholm, the Nobel Committee noted that the trio’s work identified a major source of blood-borne hepatitis that couldn’t be explained by the previously discovered hepatitis A and B viruses. Their work, dating back to the 1970s and 1980s, has helped saved millions of lives, the committee said. “Thanks to their discovery, ...
Source: TIME: Science - October 5, 2020 Category: Science Authors: DAVID KEYTON and FRANK JORDANS / AP Tags: Uncategorized News News Desk wire Source Type: news

Chemical Abstracts indexes two journals
Hepatitis B Annual and Asian Journal of Transfusion Sciences have been included in Chemical Abstracts by the Chemical Abstracts Service.December-2007 (Source: Medknow News)
Source: Medknow News - September 30, 2020 Category: Databases & Libraries Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

After big buyout, team looks to lead hepatitis B, NASH drug maker to $100M IPO
Two-year-old Aligos Therapeutics Inc. is seeking a $100 million initial public offering to help take its experimental chronic hepatitis B drugs into clinical trials. The South San Francisco company is the work of much of the executive team that translated $74 million in investments for hepatitis C-focused Alios BioPharma Inc. of South San Francisco into a $1.75 billion cash deal in 2014 with Johnson& Johnson's (NYSE: JNJ) Janssen Pharmaceutical unit. Janssen ultimately dumped Alios' oral drug,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 28, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

After big buyout, team looks to lead hepatitis B, NASH drug maker to $100M IPO
Two-year-old Aligos Therapeutics Inc. is seeking a $100 million initial public offering to help take its experimental chronic hepatitis B drugs into clinical trials. The South San Francisco company is the work of much of the executive team that translated $74 million in investments for hepatitis C-focused Alios BioPharma Inc. of South San Francisco into a $1.75 billion cash deal in 2014 with Johnson& Johnson's (NYSE: JNJ) Janssen Pharmaceutical unit. Janssen ultimately dumped Alios' oral drug,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news

Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia
SUZHOU, China and ROCKVILLE, Md., Sept. 7, 2020 -- (Healthcare Sales & Marketing Network) -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),... Biopharmaceuticals, Oncology, FDA Ascentage Pharma, APG-2575, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2020 Category: Pharmaceuticals Source Type: news

The Guardian view on African success: a step closer to conquering polio | Editorial
We are tantalisingly close to eradicating the disease. Things may slip backwards because of science, thugs and exponents of ignorancePolio arrives, if it announces itself at all, as a high temperature. Or a sore throat. Maybe a headache, or an upset stomach. It can go within a week or so, and be mistaken for flu. It is transmitted by poor hygiene, largely affects children under five, and many don ’t realise they’ve had it. In 5-10% of cases, however, the virus affects the nerves, paralysing the legs in particular; sometimes it reaches the lungs. For most, this is temporary. For others –30 years ago, this ...
Source: Guardian Unlimited Science - August 30, 2020 Category: Science Authors: Editorial Tags: Polio Vaccines and immunisation Children Pakistan Afghanistan Hepatitis B Taliban Coronavirus outbreak Infectious diseases Health Medical research Science South and Central Asia Society Source Type: news

Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020
This report describes a funding program in Uzbekistan designed to identify and treat cases of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection at a lowered cost with the goal of meeting the World Health Organization's targets to eliminate HBC and HCV infection. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - August 27, 2020 Category: American Health Tags: Hepatitis B Hepatitis C MMWR Morbidity & Mortality Weekly Report Source Type: news

The Role of the Pharmacist in Preventing Hepatitis B in the Context of the Opioid Crisis
(Source: CDC Preventing Chronic Disease)
Source: CDC Preventing Chronic Disease - August 20, 2020 Category: International Medicine & Public Health Tags: Public Health Source Type: news

Lack of continuous infectious disease pandemic research endangers responses
(American Associates, Ben-Gurion University of the Negev) The coronavirus was also studied considerably less than blood borne viruses like Hepatitis B or C and H.I.V. and its research community has less prolific researchers than the other investigated diseases. This translates into limited collaborations and a non-sustained investment in research on coronaviruses. Such a short-lived investment also reduces funding and may slow down important developments such as new drugs, vaccines or preventive strategies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 17, 2020 Category: International Medicine & Public Health Source Type: news

Busting Up the Infection Cycle of Hepatitis B
(University of Delaware) Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the " spiky ball " that encloses its genetic blueprint. They looked at how the capsid--a protein shell that protects the blueprint and also drives the delivery of it to infect a host cell--assembles itself. The capsid is an important target in developing drugs to treat hepatitis B, a life-threatening and incurable infection that afflicts more than 250 million people worldwide. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 13, 2020 Category: Biology Source Type: news

Hepatitis B: Natural controllers shed light on immunity mechanisms
(Institut Pasteur) To improve our understanding of the antibody response conferring protection against HBV infection, scientists from the Institut Pasteur and Inserm, in collaboration with the Roche Innovation Center in Switzerland, produced and characterized human monoclonal antibodies specific to viral envelope antigens, referred as HBsAg, from blood memory B cells isolated from HBV vaccinees and natural controllers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 13, 2020 Category: Biology Source Type: news

Hepatitis Screening Now for All Patients With Cancer on Therapy Hepatitis Screening Now for All Patients With Cancer on Therapy
All patients with cancer who are candidates for systemic therapy should be screened for hepatitis B, says the American Society of Clinical Oncology.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 5, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

US obesity epidemic could undermine effectiveness of a Covid-19 vaccine
Vaccines protecting against influenza, hepatitis B and rabies are less effective for obese people. As scientists develop a Covid-19 vaccine, experts say obesity could be an impediment, a sobering prospect for the US, where nearly half of all adults are obese. (Source: CNN.com - Health)
Source: CNN.com - Health - August 5, 2020 Category: Consumer Health News Source Type: news

First drug for hepatitis D has been approved by european commission
(German Center for Infection Research) The European Commission has approved Hepcludex for the treatment of chronic hepatitis D infection / Successful translation of basic research into clinical applications / entry blocker also demonstrates effectiveness against hepatitis B (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 5, 2020 Category: Biology Source Type: news

Birth dose of hepatitis B vaccine cost effective in Ethiopia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2020 Category: Drugs & Pharmacology Source Type: news

Progress Toward Hepatitis B Control - South-East Asia Region, 2016-2019
This report describes progress of countries in the World Health Organization's South-East Asia region toward reaching 90% hepatitis B vaccination coverage. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - July 30, 2020 Category: American Health Tags: Hepatitis B Hepatitis B Screening Hepatitis B Vaccination MMWR Morbidity & Mortality Weekly Report Source Type: news

Zambia: Zambia Joins the Global Community to Commemorate the World Hepatitis Day
[WHO] To mark the commemoration of the World Hepatitis Day 2020, the World Health Organization has called for a global and united effort to eliminate viral hepatitis as a public health threat by 2030. More than 1.3 million people die annually as a result of Hepatitis B and C. Zambia has therefore joined the global community to commemorate World Hepatitis Day under the theme "Hepatitis free future". The theme highlights the importance of preventing mother-to-child transmission of Hepatitis B and scaling (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 30, 2020 Category: African Health Source Type: news

Nigeria: Over 20 Million Nigerians Infected With Hepatitis - Minister
[Premium Times] About 20 million Nigerian are chronically infected with hepatitis B and C, the minister of health, Osagie Ehanire, said on Tuesday. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 30, 2020 Category: African Health Source Type: news